Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids

References

• Airaksinen MM, Kari I. (1981). Beta-carbolines, psychoactive compounds in the mammalian body. Part I: Occurrence, origin and metabolism. Med Biol 59:21–34
   PubMedGoogle Scholar
• Chen L, Pawlikowski B, Schlessinger A, et al. (2010). Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 20:687–99
   PubMed Web of Science ®Google Scholar
• Cheng Y, Martinez-Guerrero LJ, Wright SH, et al. (2011). Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo. Drug Metab Dispos 39:1755–61
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Koepsell H, Iordanova M, et al. (2005). Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 16:1562–70
   PubMed Web of Science ®Google Scholar
• Cui M, Aras R, Christian WV, et al. (2009). The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci USA 106:8043–8
   PubMed Web of Science ®Google Scholar
• Du W, Aloyo VJ, Harvey JA. (1997). Harmaline competitively inhibits [3H]MK-801 binding to the NMDA receptor in rabbit brain. Brain Res 770:26–9
   PubMed Web of Science ®Google Scholar
• Duan H, Hu T, Foti RS, et al. (2015). Potent and selective inhibition of plasma membrane monoamine transporter by HIV protease inhibitors. Drug Metab Dispos 43:1773–80
   PubMedGoogle Scholar
• Duan H, Wang J. (2010). Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 335:743–53
   PubMed Web of Science ®Google Scholar
• Engel K, Wang J. (2005). Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68:1397–407
   PubMed Web of Science ®Google Scholar
• Fekkes D, Bode WT. (1993). Occurrence and partition of the beta-carboline norharman in rat organs. Life Sci 52:2045–54
   PubMed Web of Science ®Google Scholar
• Fekkes D, Tuiten A, Bom I, Pepplinkhuizen L. (2001). Pharmacokinetics of the beta-carboline norharman in man. Life Sci 69:2113–21
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2012). Draft guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Food and Drug Administration. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf
   Google Scholar
• Gearhart DA, Neafsey EJ, Collins MA. (2002). Phenylethanolamine N-methyltransferase has beta-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson’s disease. Neurochem Int 40:611–20
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Tweedie DJ, Huang SM, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Glennon RA, Dukat M, Grella B, et al. (2000). Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 60:121–32
   PubMed Web of Science ®Google Scholar
• Gockler N, Jofre G, Papadopoulos C, et al. (2009). Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276:6324–37
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, et al. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–81
   PubMed Web of Science ®Google Scholar
• Hamann J, Rommelspacher H, Storch A, et al. (2006). Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture. J Neurochem 98:1185–99
   PubMed Web of Science ®Google Scholar
• Herraiz T. (2000a). Tetrahydro-beta-carboline-3-carboxylic acid compounds in fish and meat: possible precursors of co-mutagenic beta-carbolines norharman and harman in cooked foods. Food Addit Contam 17:859–66
   PubMed Web of Science ®Google Scholar
• Herraiz T. (2000b). Tetrahydro-beta-carbolines, potential neuroactive alkaloids, in chocolate and cocoa. J Agric Food Chem 48:4900–4
   PubMed Web of Science ®Google Scholar
• Herraiz T. (2004). Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. Food Addit Contam 21:1041–50
   PubMedGoogle Scholar
• Herraiz T, Gonzalez D, Ancin-Azpilicueta C, et al. (2010). Beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol 48:839–45
   PubMed Web of Science ®Google Scholar
• Herraiz T, Guillen H, Galisteo J. (2013). Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-beta-carboline by oxidative enzymes. Biomed Res Int 2013:248608
   PubMed Web of Science ®Google Scholar
• Hillgren KM, Keppler D, Zur AA, et al. (2013). Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 94:52–63
   PubMed Web of Science ®Google Scholar
• Ho HTB, Pan Y, Cui Z, et al. (2011). Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter. J Pharmacol Exp Ther 339:376–85
   PubMed Web of Science ®Google Scholar
• Ito S, Kusuhara H, Yokochi M, et al. (2012). Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340:393–403
   PubMed Web of Science ®Google Scholar
• Jiang XL, Shen HW, Mager DE, Yu AM. (2013). Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos 41:975–86
   PubMed Web of Science ®Google Scholar
• Kido Y, Matsson P, Giacomini KM. (2011). Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548–58
   PubMed Web of Science ®Google Scholar
• Kim H, Sablin SO, Ramsay RR. (1997). Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 337:137–42
   PubMed Web of Science ®Google Scholar
• Koepsell H. (2013). The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med 34:413–35
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmaceut Res 24:1227–51
   PubMed Web of Science ®Google Scholar
• Li M, Anderson GD, Wang J. (2006). Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2:505–32
   PubMed Web of Science ®Google Scholar
• Louis ED, Jiang W, Gerbin M, et al. (2010). Relationship between blood harmane and harmine concentrations in familial essential tremor, sporadic essential tremor and controls. Neurotoxicology 31:674–9
   PubMed Web of Science ®Google Scholar
• Mason JN, Farmer H, Tomlinson ID, et al. (2005). Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J Neurosci Methods 143:3–25
   PubMed Web of Science ®Google Scholar
• Matsubara K, Collins MA, Akane A, et al. (1993). Potential bioactivated neurotoxicants, N-methylated beta-carbolinium ions, are present in human brain. Brain Res 610:90–6
   PubMed Web of Science ®Google Scholar
• Matsubara K, Kobayashi S, Kobayashi Y, et al. (1995). beta-Carbolinium cations, endogenous MPP + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson’s disease. Neurology 45:2240–5
   PubMed Web of Science ®Google Scholar
• McKenna DJ. (2004). Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 102:111–29
   PubMed Web of Science ®Google Scholar
• Meyer MR, Caspar A, Brandt SD, Maurer HH. (2014). A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 ??-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal Bioanal Chem 406:225–37
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Stocker SL, Wittwer MB, et al. (2013). Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503–29
   PubMed Web of Science ®Google Scholar
• Motohashi H, Inui K. (2013). Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 15:581–8
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. (2011). Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201:105–67
   PubMedGoogle Scholar
• Nussberger J, Fasanella D’amore T, Porchet M, et al. (1987). Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol 9:39–44
   PubMed Web of Science ®Google Scholar
• Oliveira CD, Okai GG, da Costa JL, et al. (2012). Determination of dimethyltryptamine and beta-carbolines (ayahuasca alkaloids) in plasma samples by LC-MS/MS. Bioanalysis 4:1731–8
   PubMed Web of Science ®Google Scholar
• Parker CA, Anderson NJ, Robinson ES, et al. (2004). Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry 43:16385–92
   PubMed Web of Science ®Google Scholar
• Pfau W, Skog K. (2004). Exposure to beta-carbolines norharman and harman. J Chromatogr B Analyt Technol Biomed Life Sci 802:115–26
   PubMed Web of Science ®Google Scholar
• Riba J, McIlhenny EH, Valle M, et al. (2012). Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal 4:610–16
   PubMed Web of Science ®Google Scholar
• Riba J, Valle M, Urbano G, et al. (2003). Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306:73–83
   PubMed Web of Science ®Google Scholar
• Richling E, Herderich M, Schreier P. (1996). High performance liquid chromatography —Electrospray tandem mass spectrometry (HPLC-ESI-MS-MS) for the analysis of heterocyclic aromatic amines (HAA). Chromatographia 42:7–11
   Web of Science ®Google Scholar
• Robinson ES, Anderson NJ, Crosby J, et al. (2003). Endogenous beta-carbolines as clonidine-displacing substances. Ann N Y Acad Sci 1009:157–66
   PubMed Web of Science ®Google Scholar
• Rommelspacher H, May T, Salewski B. (1994). Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol 252:51–9
   PubMed Web of Science ®Google Scholar
• Smith KL, Ford GK, Jessop DS, Finn DP. (2013). Behavioural, neurochemical and neuroendocrine effects of the endogenous β-carboline harmane in fear-conditioned rats. J Psychopharmacol (Oxford) 27:162–70
   PubMed Web of Science ®Google Scholar
• Storch A, Hwang YI, Gearhart DA, et al. (2004). Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson’s disease: relationship to transporter-dependent uptake. J Neurochem 89:685–94
   PubMed Web of Science ®Google Scholar
• Totsuka Y, Ushiyama H, Ishihara J, et al. (1999). Quantification of the co-mutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods. Cancer Lett 143:139–43
   PubMed Web of Science ®Google Scholar
• Wagner DJ, Hu T, Wang J. (2016). Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res 111:237–46
   PubMed Web of Science ®Google Scholar
• Wu C, Jiang XL, Shen HW, Yu AM. (2009). Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol 78:617–24
   PubMed Web of Science ®Google Scholar
• Yang YJ, Lee JJ, Jin CM, et al. (2008). Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol 587:57–64
   PubMed Web of Science ®Google Scholar
• Yin J, Duan H, Shirasaka Y, et al. (2015). Atenolol renal secretion is mediated by human organic cation transporter 2 and multidrug and toxin extrusion proteins. Drug Metab Dispos 43:1872–81
   PubMed Web of Science ®Google Scholar
• Yu AM. (2008). Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 10:242–53
   PubMed Web of Science ®Google Scholar
• Zhang L, Reynolds KS, Zhao P, Huang SM. (2010). Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 243:134–45
   PubMed Web of Science ®Google Scholar
• Zhao T, He YQ, Wang J, et al. (2011). Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother Res 25:1671–7
   PubMed Web of Science ®Google Scholar